Women of childbearing age who experience various forms of menstrual disorders followed by amenorrhea, infertility, or lactation should be alerted to pituitary prolactinomas. Prolactinomas are the most common pituitary tumor, accounting for 80% to 85% of pituitary tumors. There are 5 times more females than males, and 2/3 of female patients have microadenomas, mostly between the ages of 20 and 40. The clinical manifestations of pituitary prolactinoma are the triad of menstrual disorders – overflow – infertility: 1. Menstrual disorders. Normal concentration of prolactin (PRL) has a pro-luteal effect, but high concentration of prolactin (PRL) can directly or indirectly inhibit the pulsatile release of gonadotropin-releasing hormone (GnRH), resulting in reduced or absent pulsatile secretion of luteinizing hormone (LH). PRL also decreases GnRH receptors on the surface of pituitary gonadotropin cells and causes ovarian receptors to resist gonadotropin hormones, resulting in lower estrogen levels in the blood. 5-7% of patients with prepubertal onset present with primary amenorrhea, while those with postpubertal onset first have shortened luteal phase and anovulatory menstruation, followed by scanty menstruation, and finally secondary amenorrhea. About 1/3 of female patients with secondary amenorrhea (including those who stop the pill) have a pituitary PRL tumor, which grows during pregnancy, and 15% of patients are first diagnosed after delivery. 2. Breast overflow. About 1/3 to 1/2 of patients have overflowing milk, i.e., milky white or yellowish fluid flowing from the nipple, and only a small amount of milk overflowing when the breast is squeezed. Since the development of the mammary glands and the secretion of milk depend on the combined effects of prolactin, estrogen, progesterone, growth hormone and glucocorticoids, some patients with high PRL may not have breast milk overflow. Most of the patients who only have overflowing breast but no amenorrhea do not have hyper-PRLemia. 3. Infertility. Hypo-PRLemia inhibits the peak of LH and ovulation due to positive estrogen feedback, resulting in infertility. The miscarriage rate in patients with pituitary PRL tumors can be as high as 30%. 4. Sexual dysfunction. Patients with reduced blood estrogen levels, about 60% of patients have hypoactive or absent libido, loss of sensuality, and absence of orgasm. The vaginal mucosa is atrophied and sexual intercourse is difficult. 5.Other. About 1/4 patients have polycystic ovaries, weight gain, acne and hirsutism, moderate increase in urinary 17-ketosteroids and dehydroisoandrosterone sulfate excretion. Due to low estrogen levels, patients may have osteoporosis. Some patients also have metabolic disorders such as obesity, water retention, and reduced glucose tolerance. The clinical manifestations of cerebral prolactinoma are divided into two main aspects: endocrine changes and tumor dominant effects. Although the syndrome of “menstrual disorders – breast milk overflow – infertility” has been noticed for a long time, it has not been considered as an early symptom of hypogonadism and has not been associated with pituitary tumor, so it is often ignored by patients or considered by doctors as “functional” and delayed. “The diagnosis of hypogonadism is often delayed because it is not considered as an early symptom and is not associated with pituitary tumor. As a result, the tumor is often found only when the tumor has an occupying effect, and in some cases, the tumor is already very large and the best time for treatment is lost. Therefore, once a woman of childbearing age develops menstrual disorders, and such menstrual disorders are often prolonged cycles, this is the time to pay attention to it, and both from the doctor’s and patient’s point of view must be alert to the possibility of pituitary prolactinoma. The diagnosis of pituitary prolactinoma is not difficult with the combination of clinical manifestations, blood PRL level, PRL secretion function test and MR imaging, and is only a common disease in neurology. The proportion of female patients with pituitary lactinoma is high, and 90% of them are pituitary microadenomas. Therefore, more and more experts are focusing on improving the cure rate of pituitary microadenomas, and early treatment can suppress the occupying effect of the tumor. In general, pituitary microadenoma, due to the small size of the tumor, some only in the glandular hyperplasia, no surgical indication, has been using the treatment of bromocriptine, but long-term use of bromocriptine, many side effects, once you stop taking, the symptoms again. As the efficacy of Chinese medicine in treating pituitary microadenoma continues to emerge, more experts have adopted a combination of Chinese and Western medicine to treat pituitary microadenoma. The treatment was started with bromocriptine + herbal medicine. After the menstruation is normalized and PRL level decreases, the amount of bromocriptine is gradually reduced until bromocriptine is replaced by Chinese herbal medicine. The synergistic treatment of Chinese and Western medicine not only can reduce the side effects after taking bromocriptine, but also can restore normal menstruation and enable conception and childbirth by regulating the flushing of the body, removing stasis and phlegm, and eliminating swelling and dissipating nodules through individual diagnosis and analysis of Chinese medicine.